Hubei Duorui Pharmaceutical

Hubei Duorui Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, production, and sale of chemical drug preparations. The company's core business is centered on plasma substitutes, with its flagship product being Hydroxyethyl Starch 130/0.4 Electrolyte Injection, used for treating hypovolemia and shock. Beyond critical care, Duorui's portfolio includes anti-infectives, cardiovascular treatments, and digestive system medications. The company operates a vertically integrated model with dedicated R&D centers in Wuhan and manufacturing facilities in Jingmen. Listed on the Shenzhen Stock Exchange in 2021, Duorui continues to focus on the domestic Chinese market through the development of high-quality generics and improved therapeutic formulations.